BC 007 - Dragonboat Biopharmaceutical
Alternative Names: Anti-CLDN 18.2/CD47 bi-specific antibody - Dragonboat Biopharmaceutical; BC-007 - Dragonboat Biopharmaceutical; CLDN 18.2/CD47 bsAb - Dragonboat BiopharmaceuticalLatest Information Update: 28 Jun 2022
At a glance
- Originator Dragonboat Biopharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 28 Jun 2022 Safety and pharmacodynamics data from preclinical studies in solid tumors released by Dragonboat Biopharmaceutical
- 25 Jun 2022 Preclinical trials in Solid tumours in China (Parenteral) (Dragoncoat Biopharmaceutical pipeline, June 2022)
- 25 Jun 2022 Dragonboat Biopharmaceutical files a clinical trial application (CTA) with the National Medical Products Administration (NMPA) in China for solid tumours (Late-stage disease) prior to June 2022